MedTrace Logo

Allopurinol Maintenance Study for Bipolar Disorder

NCT00732251 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-10-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for the prevention of mania in bipolar disorder patients with currently stable mood.

Conditions

Interventions

DRUG

Allopurinol

Allopurinol: 300-600 mg/day over a 24 month period

Sponsors & Collaborators

  • West Coast College of Biological Psychiatry Inc

    collaborator UNKNOWN

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Itai Danovitch, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00732251 on ClinicalTrials.gov